NASDAQ:BGNE - Beigene Stock Price, Forecast & News

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Beigene Ltd (NASDAQ:BGNE) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($5.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.56) by $1.55. The company earned $50.14 million during the quarter, compared to analyst estimates of $65.43 million. Beigene had a negative net margin of 192.75% and a negative return on equity of 53.11%. The company's revenue was down 7.5% on a year-over-year basis. During the same period in the prior year, the company earned ($2.53) earnings per share. View Beigene's Earnings History.

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Beigene.

11 Wall Street analysts have issued 12 month price objectives for Beigene's stock. Their forecasts range from $165.00 to $230.00. On average, they expect Beigene's stock price to reach $208.03 in the next year. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Price Targets for Beigene.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

Press coverage about BGNE stock has been trending neutral recently, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beigene earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Beigene.

Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL) and Ono Pharmaceutical (OPHLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Tesla (TSLA), TENCENT HOLDING/ADR (TCEHY), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX).

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (8.85%), Capital International Investors (7.45%), Capital International Inc. CA (1.57%), State Street Corp (1.25%), Janus Henderson Group PLC (0.59%) and Alliancebernstein L.P. (0.50%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Alliancebernstein L.P., Sands Capital Management LLC, Citigroup Inc., Victory Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Insider Buying and Selling for Beigene.

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Pictet Asset Management Ltd., Ariose Capital Management Ltd, Bank of America Corp DE, Renaissance Technologies LLC, Partners Capital Investment Group LLP, Cubist Systematic Strategies LLC and Matthews International Capital Management LLC. View Insider Buying and Selling for Beigene.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $163.96.

Beigene has a market capitalization of $10.01 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.

The official website for Beigene is http://www.beigene.com/.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]